drugset / Trial / NCT04828616
Study of DP303c Injection in Patients With Advanced Ovarian Cancer
NaSingle-groupOpen-labelTreatment
Summary
This study is an open-label, multicentre, phase II study to evaluate the efficacy and safety of of DP303c injection in patients with HER2-expressing advanced ovarian cancer.
Timeline
- Start
- 2021-07
- Primary completion
- 2023-07
- Completion
- 2024-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | TRASTUZUMAB ENVEDOTIN | Monoclonal antibody | 2 mg/kg | — |
| Subject | TRASTUZUMAB ENVEDOTIN | Monoclonal antibody | 3 mg/kg | — |